Lpath Inc. (LPTN.OB) Receives Key Patents from U.S. and European Patent Offices

QualityStocks would like to highlight Lpath Inc. (OTCBB: LPTN). The company has achieved a broad and deep intellectual-property position in the bioactive-lipid area. The company's comprehensive patent portfolio now includes 20 issued patents (including four international) and 105 patent applications (including 70 international). These patents primarily concern the use of reagents and methods designed to interfere with the actions of bioactive lipids involved in human disease.

In the company’s news yesterday,

Lpath Inc. announced it has received official notification from the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO) that the company has been issued two key patents related to ASONEP™, one of the Lpath’s two lead drug candidates.

ASONEP is a therapeutic antibody developed by Lpath’s ImmuneY2™ drug-discovery engine. The antibody is designed to target bioactive signaling lipids that are associated with the proliferation and spread of cancer and other diseases.

“By issuing these patents, the USPTO and EPO have further validated the novelty and utility of Lpath’s use of S1P-neutralizing monoclonal antibodies for the diagnosis and treatment of multiple and diverse diseases,” Dr. Laurel Bernstein, executive director of intellectual property for Lpath stated in the press release.

Lpath recently completed two early-stage clinical trials: iSONEP was evaluated in a phase I trial in wet-AMD subjects; ASONEP was evaluated in a phase I trial in cancer subjects. Lpath now plans on conducting two iSONEP phase II trials, one in patients with RPE Detachment (PED), for which the company says there is no approved treatment, and another in wet-AMD patients without PED.

Lpath last year entered into an agreement with Pfizer (NYSE: PFE) in which Pfizer has exclusive worldwide license rights to develop and commercialize iSONEP.

“Lpath now has patent protection not only on our drug candidates, iSONEP and ASONEP, but also on the methods of use in the treatment of several ocular diseases, as well as cancer, cardiac, autoimmune, and inflammatory disorders. The strength of Lpath’s patent portfolio is key to the successful commercialization of both iSONEP and ASONEP,” Roger Sabbadini, Lpath’s chief scientific officer and main inventor of the issued patents stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.